Attached files
| file | filename |
|---|---|
| EX-99.2 - CALADRIUS BIOSCIENCES, INC. | v225743_ex99-2.htm |
| EX-99.1 - CALADRIUS BIOSCIENCES, INC. | v225743_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2011
NEOSTEM, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
(State or Other Jurisdiction
of Incorporation)
|
001-33650
(Commission
File Number)
|
22-2343568
(IRS Employer
Identification No.)
|
420 Lexington Avenue, Suite 450, New York, New York 10170
(Address of Principal Executive Offices)(Zip Code)
(212) 584-4180
Registrant's Telephone Number
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure.
On June 13, 2011, NeoStem, Inc. (“NeoStem” or the “Company”) issued a press release providing an update on Suzhou Erye Pharmaceutical Company Ltd., the pharmaceutical company in which NeoStem holds a 51% interest. A copy of the press release is being furnished as Exhibit 99.1 hereto.
NeoStem intends, from time to time, to utilize at various industry and other conferences a slide presentation. The slide presentation is accessible on NeoStem’s website at www.neostem.com and is being furnished as Exhibit 99.2 hereto. NeoStem undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.
The information in this Current Report on Form 8-K under Item 7.01 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including, without limitation, Exhibits 99.1 and 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K, including, without limitation, Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
Forward-Looking Statements
This Current Report on Form 8-K, including Exhibits 99.1 and 99.2 hereto, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions, although some forward-looking statements are expressed differently. Forward-looking statements represent the Company's management's judgment regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. All statements other than statements of historical fact included in the Current Report on Form 8-K are forward-looking statements. The Company cannot guarantee the accuracy of the forward-looking statements, and you should be aware that the Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the statements under "Risk Factors" contained in the Company's reports filed with the Securities and Exchange Commission.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release, dated June 13, 2011*
|
|
|
99.2
|
Slide Presentation of NeoStem, Inc., dated June 2011* |
*Exhibits 99.1 and 99.2 are furnished as part of this Current Report on Form 8-K.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, NeoStem, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEOSTEM, INC.
|
|||
|
By:
|
/s/ Catherine M. Vaczy
|
||
|
Name: Catherine M. Vaczy
|
|||
|
Title: Vice President and General Counsel
|
|||
Date: June 13, 2011
-3-
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release, dated June 13, 2011*
|
|
|
99.2
|
Slide Presentation of NeoStem, Inc., dated June 2011* |
*Exhibits 99.1 and 99.2 are furnished as part of this Current Report on Form 8-K.
-4-